NCT07709416 Toludesvenlafaxine for Non-specific Low Back Pain
| NCT ID | NCT07709416 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beijing Tiantan Hospital |
| Condition | Non-specific Low Back Pain |
| Study Type | INTERVENTIONAL |
| Enrollment | 132 participants |
| Start Date | 2026-07-15 |
| Primary Completion | 2028-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 132 participants in total. It began in 2026-07-15 with a primary completion date of 2028-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Chronic non-specific low back pain is the leading cause of productivity loss and disability worldwide, constituting a major public health challenge. This study aims to systematically evaluate and compare the role of the antidepressant drug toludesvenlafaxine in chronic non-specific low back pain, which is of critical importance for optimising clinical practice and developing precise, individualised treatment regimens.
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 to 75 years. * Diagnosis of chronic nonspecific low back pain, defined as pain located below the costal margin and above the inferior gluteal folds, lasting for more than 3 months, without a specific pathological cause. * Moderate to severe pain, defined as a Numerical Rating Scale score of 3 or higher. * Able to understand the study procedures and sign written informed consent. Exclusion Criteria: * Low back pain caused by a known specific pathological condition, including but not limited to fracture, malignancy, infection, inflammatory disease, or other identifiable structural or systemic causes. * Major comorbidities that may interfere with study outcomes or represent contraindications to the study medication. * Current or previous diagnosis of depression, regardless of whether treatment was received. * Current or previous use of antidepressant medication. * Current use of opioid analgesics. * Pregnancy, breastfeeding, or planned pregnancy during the study period. * Known allergy, hypersensitivity, or contraindication to toludesvenlafaxine. * History of psychosis or other major psychiatric disorders. * Any condition that, in the investigator's judgment, makes the participant unsuitable for the study.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07709416 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Non-specific Low Back Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07709416 currently recruiting?
Yes, NCT07709416 is actively recruiting participants. Contact the research team at 13611326978@163.com for enrollment information.
Where is the NCT07709416 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07709416 clinical trial?
NCT07709416 is sponsored by Beijing Tiantan Hospital. The trial plans to enroll 132 participants.